相关实验视频

Updated: Feb 18, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

针对Dickkopf-1-A2复合物的T细胞可以用于治疗HLA-A2固体和血液癌症

Yufei Zhang¹, Wei Xiong¹, Jianfei Qian¹

¹Center for Translational Research in Hematological Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Research Institute, Houston, TX, USA.

Nature communications

|February 16, 2026

概括

针对Dickkopf-1 (DKK1) 蛋白质的新仿真抗原受体 (CAR) -T细胞显示出对固体瘤的希望. 在没有显著毒性的模型中,DKK1-A2 CAR-T细胞有效地消除了各种癌症.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

化学抗原受体 (CAR) -T细胞疗法对血液瘤有效,但在固体瘤中面临挑战.
Dickkopf-1 (DKK1) 蛋白质是一个有前途的标,因为它在许多血液和固体瘤上表达.
HLA-A2是一种常见的人类白细胞抗原,在瘤细胞上发现.

研究的目的:

开发和评估DKK1-A2 CAR-T细胞,以向表达DKK1和HLA-A2.2的固体瘤.
在临床前癌症模型中评估DKK1-A2CAR-T细胞的疗效和安全性.

主要方法:

使用针对DKK1-A2复合体的抗体生成DKK1-A2CAR-T细胞.
测试了对HLA-A2+瘤细胞和健康的供体细胞的CAR-T细胞特异性.
在人类骨髓瘤,胰腺癌,肺癌和乳腺癌的异种移植模型中评估了DKK1-A2 CAR-T细胞的疗效.

主要成果:

DKK1-A2 CAR-T细胞专门溶解了表达HLA-A2和DKK1的瘤细胞.
没有观察到来自健康HLA-A2+捐赠者的血液或骨髓细胞的溶解.
在各种异种移植模型中,DKK1-A2 CAR-T细胞控制或根除了已有的瘤.
在NSG或转基因小鼠模型中没有观察到可检测的毒性.

结论:

DKK1-A2 CAR-T细胞表现出针对固体瘤的特定和有效的抗瘤活性.
这些CAR-T细胞代表了治疗表达DKK1和HLA-A2的人类癌症的潜在新疗法策略.
需要对DKK1-A2CAR-T细胞进行进一步的临床研究.

更多相关视频

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.